In this manuscript we discuss a chemical kinetic model of blood coagulation by treatment with nonequilibrium atmospheric pressure dielectric barrier discharge. We then add kinetic data into a computational fluid dynamics model of blood flow treated by plasma and show that we are able to induce hemostasis. We then present initial experimental validation of these computational models using in vitro bovine blood samples.
I. INTRODUCTION
Over 40% of combat-related deaths are attributable to uncontrolled bleeding, the majority of those from noncompressible profuse hemorrhage. 1, 2 Of the two main current conventional approaches, thermal coagulation creates extensive tissue damage unacceptable for noncompressible combat wounds, while various powder-based coagulants have absorbance capacity that is easily overcome by profuse hemorrhage. Thus, the combat medic requires breakthrough novel tools that effectively stop massive bleeding and that they can employ rapidly and easily. We have recently developed such a breakthrough novel device based on nonthermal nanosecond-pulsed plasma applied directly to a bleeding wound surface. [3] [4] [5] In this paper we simulate, investigate, and optimize the dynamics of flowing and coagulating blood for the case of profuse hemorrhage undergoing direct pulsed plasma treatment, and discuss a prototype system that a combat medic can apply to a real, complex, three-dimensional profusely bleeding wound.
II. BACKGROUND A. Nonthermal Plasma-assisted Hemostasis
Recently, a new method has been developed and demonstrated for controlling applied high voltages in nanosecond pulses in order to stabilize a powerful nonequilibrium plasma, making it sufficiently uniform to be directly applied to cells and living tissues without thermal destruction. 6, 7 This important innovation is the breakthrough that enables our team to demonstrate effective plasma stimulation of hemostasis, tissue regeneration, and wound healing. 3, 8, 9 Effective plasma stimulation of in vivo blood coagulation has been demonstrated in experiments with live SKH1 mice. Fifteen seconds of Floating Electrode-Dielectric Barrier Discharge (FE-DBD) plasma treatment is able to coagulate blood at the surface of a cut saphenous vein as well as tail vein of a mouse. 5 In these experiments, only the ability of direct nonthermal plasma treatment to coagulate blood was tested, and the animal was not left alive to test improvement in healing times.
It was demonstrated that direct nonthermal plasma can trigger natural, rather than thermally induced, coagulation processes. 7 It was also observed that the release of calcium ions and change of blood pH level, which could be responsible for coagulation, is insignificant. Instead, the evidence points to selective action of direct nonthermal plasma on blood proteins involved in natural coagulation processes.
Mechanisms of plasma interaction with blood can be deduced from the following facts observed in the experiments with FE-DBD plasma: (1) Plasma can coagulate both normal and anticoagulated blood, but the rate of coagulation depends on the anticoagulant used; (2) plasma is able to alter ionic strength of the solution and change its pH, but normal and anticoagulated blood buffers these changes even after relatively long treatment times; (3) plasma changes the natural concentration of clotting factors significantly, thus promoting coagulation; (4) effects delivered by plasma are nonthermal and are not related to gas temperature or the temperature at the surface of blood; (5) plasma is able to promote platelet activation and formation of fibrin filaments, even in anticoagulated blood. These experimental facts are discussed in further detail below.
(1) Anticoagulants like sodium heparin bind thrombin in the coagulation cascade thus slowing coagulation, while sodium citrate or ethylene diamine tetraacetic acid (EDTA), are designed to bind calcium, an important factor in the cascade, thereby preventing coagulation altogether. Plasma treatment promotes visible coagulation in the presence of all of the above anticoagulants.
(2) Previously, plasma coagulation hypotheses were focused on increases in the concentration of Ca 2+ , which is an important factor in the coagulation cascade. It was suggested that plasma stimulates generation of Ca 2+ through the redox mecha-nism provided by hydrogen ions produced in blood in a sequence of ion-molecular processes induced by plasma ions. Validity of the hypothesis was tested experimentally by measuring Ca 2+ concentration in the plasma-treated anticoagulated whole blood using a calcium-selective microelectrode. Calcium concentration was measured immediately after plasma treatment and remained almost constant for up to 30 s of treatment and then increased slightly for prolonged treatment times of 60 and 120 s. Although plasma is capable of coagulating anticoagulated blood within 15 s, no significant change occurs in calcium ion concentration during the typical time of blood coagulation in discharge treated blood. In vivo, the pH of blood is maintained in a very narrow range of 7.35-7.45 by various physiological processes. The change in pH by plasma treatment (about 0.1 after 30 s) is less than the natural variation of pH, which indicates that the coagulation is probably not due to the pH change in blood.
(3) FE-DBD treatment of whole blood samples was shown to change concentrations of various proteins participating in the coagulation cascade. Plasma treatment is shown to "consume" coagulation factors (proteins and enzymes) and a visible film is formed on the surface of the treated samples. The plasma treatment effect was diminished by either increasing the sample volume or keeping the surface area fixed, indicating that plasma treatment initiates clot formation at the surface, not throughout the volume. A corresponding kinetic model of the plasma-assisted blood coagulation indicates a twofold decrease in clot formation time with plasma treatment. 5 (4) When the surface of blood is protected by a thin aluminum foil, which prevents contact between blood and FE-DBD plasma but transfers all the heat generated by plasma, no influence on blood is observed. This suggests a nonthermal mechanism of the plasma-stimulated blood coagulation.
(5) The final step in the natural biological process of blood coagulation is the production of thrombin which converts fibrinogen into fibrin monomers that polymerize to form fibrin microfilaments. FE-DBD plasma treatment of fibrinogen solution in physiological medium coagulates it, which is confirmed visually through a change in the color of the solution (from clear to milky-white) and through dynamic light scattering. 10 Of note is that plasma does not influence fibrinogen through a pH or temperature change. FE-DBD treatment, however, is unable to polymerize albumin (directly not participating in coagulation cascade) as no change in its behavior is observed both visually and through dynamic light scattering (DLS). Thus nonthermal plasma selectively affects proteins (specifically, fibrinogen) participating in the natural coagulation mechanism. Morphological examination of the clot layer by scanning electron microscopy (SEM) further proves that plasma does not "cook" blood, but initiates and enhances natural sequences of blood coagulation processes. Activation followed by aggregation of platelets is the initial step in the coagulation cascade and conversion of fibrinogen into fibrin is the final step in the coagulation cascade. It was shown that the extensive platelet activation, platelet aggregation, and fibrin formation follows after the FE-DBD plasma treatment. 
III. MATERIALS AND METHODS

A. Computational Fluid Dynamics (CFD) Model
To create a suitable computational model of the biochemical phenomenon of blood coagulation, various modeling approaches, geometries, and methods were evaluated. COMSOL 4.3 Multiphysics solver was used together with a 3D flow-through pipe model. Changes in blood viscosity induced by plasma treatment were modeled through the introduction of a point source of heat into the flow and the liquid was given a temperature-dependent viscosity.
B. Kinetic Coagulation Model
MATLAB was used to solve the governing reactions in blood coagulation with respect to time. These reactions were taken from a blood coagulation model that was previously developed by Fridman et al. 5 This mathematical model determines the rate of reaction of the different factors used to create thrombin among other factors that assist in the coagulation of blood. In this kinetic model the effect of plasma is introduced through rate increase of reactions related to calcium ion release from blood cells as was previously reported.
3,5 A second model is currently being developed to include the reactions associated with platelet activation.
C. Measurements of Calcium Ion Concentration in In Vitro Blood Samples
Four samples of bovine blood (Lampire Biological Laboratories, Pipersville, PA) were tested to obtain baseline concentration of calcium ions. Each sample was prepared using a chromogenic reagent and a calcium assay buffer kit (BioVision Incorporated, Milpitas, CA). The reagent included o-cresolphthalein which, when reacted with calcium ions, forms a chromogenic complex identifiable at 575 nm. All samples were prepared in 75 μL microcuvettes.
A standard curve was created using a calcium standard diluted with distilled water to give samples of 0, 1.2, 2, and 4 μg Ca 2+ /mL. Blood samples were measured using a UV-Vis Spectrophotometer (Hitachi U-2900 Double Beam Spectrophotometer). Preparation involved mixing 50 μL of sample, 90 μL chromogenic reagent, and 60 μL calcium assay buffer in a cuvette. The reaction was incubated for 10 min and then measured at 575 nm. Absorbance measurements obtained were correlated with the concentration of Ca 2+ using the standard curve. See Table 1 .
D. Measurement of Power Dissipated in the Discharge
The DBD device, constructed based on the schematics introduced by Fridman et al., 5 was connected to a transformer to easily manipulate the electrode power output. The electrode wire was placed through an ammeter and connected through a voltage probe to power resistors with a total impedance of 300 kΩ. This impedance was selected as an approximation of the impedance from the electrode treatment of dry (no additional moisture) skin. 11 The measurements from the ammeter and the voltage probe where both used to calculate the power dissipated in the discharge.
E. Countering the Effect of Anticoagulant in Blood
The in vitro blood samples used in this experimental study were anticoagulated by EDTA (ethylenediaminetetraacetic acid). EDTA binds calcium ions and thus prevents coagulation cascade activation. Satchidanandam et al. report that addition of 4 mM Ca 2+ countered the effect of EDTA and allowed blood to coagulate normally. 12 As such, the concentration of calcium chloride needed to counteract the EDTA anticoagulant added to the blood for preservation was calculated as part of this study. Twelve vials were filled with 4 mL of bovine blood. A 70 mM solution of anticoagulant neutralizer (ACN) was prepared using high-purity calcium chloride. This base solution was titrated with saline in order to dilute further test solutions to produce desired concentrations. All of the blood samples were heated at 37°C for 30 min before testing. Once at the appropriate temperature, 100 μL of the ACN solutions were added to the blood vials. The vials were then placed in an upright stand and observed every minute until coagulation: Once the entire volume of the test tube solidified the blood was deemed coagulated.
F. Blood Viscosity Measurement
As blood is coagulating, its viscosity changes drastically and thus we opted to use the viscosity change as an indicator of coagulation (viscosity was measured by Hemathix Blood Analyzer SCV-200, Health Onvector Inc., Camden, NJ). Vials were each filled with 4 mL of bovine blood and constituted with 100 μL of ACN solution to counteract the anticoagulant effects. Subsequently, each blood sample was poured into a dish and exposed to plasma (see schematic in Fig. 1 and photograph of the treatment procedure in Fig. 2 ). After exposure, the sample viscosity was measured using the Hemathix automated scanning capillary viscometer. 
G. Plasma Treatment of Flowing Blood
To validate plasma treatment of flowing blood we have constructed a setup simulating a bleeding arteriole of ~1.5 mm diameter. To accomplish this we have placed 100 mL of blood with ACN solution 30 cm above the laboratory benchtop surface and allowed it to flow through a channel cut in an aluminum plate (Figs. 3 and 4) . In this setup, approximate pressure at the "bleeding cut" is 25 mmHg which is comparable to the cut arteriole blood pressure. The channel was covered with a dielectric film with a ~1.5 mm hole punched in it to simulate a cut.
IV. RESULTS AND DISCUSSION
A. Computational Fluid Dynamics Model of Plasma-assisted Coagulation of Flowing Blood
Simple pipe flow simulations were successfully carried out. The challenging portion of creating this model was finding a physical mechanism that replicated blood coagula- tion in COMSOL 4.3 using the available modules. The initial mechanism attempted to change blood viscosity over time. This was done using a point heat source applied to the surface of the pipe and changing the physical properties of the working fluid to increase viscosity with temperature. The "heat transfer in fluids" physics module was employed to apply the point heat source. The rate at which temperature changed viscosity was given by an exponential function called "viscRate" as seen in Eq. (1). viscRate = 0.035*exp(k*T)
Eq. 1
The 0.035 is the original blood viscosity in centipoise, k is a selected constant, and T is the temperature of the fluid. This model, shown in Fig. 5 , continuously failed to converge when solving its mesh if the selected k constant of the viscRate equation defined above was given significant weight.
Following the initial experience the model was modified. The focus was redirected to finding a working coagulation mechanism. The new geometry was changed to a 2D pipe 2 cm in diameter and 8 cm long. This model would represent a large group of vessels and a wider system of blood flow. Once again water was the working fluid and non-Newtonian physics was ignored. Free and porous flow physics was employed. A cross section in the center of the pipe was designated as the porous matrix. A second outlet was added to the model as the same position as the porous matrix. This outlet simulated the presence of a cut on the surface of the flow system. The cut outlet is 1 cm wide, representing a wound of moderate severity. Using the same initial conditions as the previous model, the goal of this model was not to change the fluid properties but to change the characteristics of the porous matrix over time. Using heat transfer, the porous matrix would decrease in porosity over time, eventually stopping flow to the cut outlet. Visible in Fig. 6 , the simulation run based on these parameters represented the process of coagulation mathematically as reductions in porosity, with the wound closing over time starting from the point heat source placed on the edge of the cut.
The coagulation mechanism was expanded to include plasma treatment considerations. In normal coagulation, generation of the chemical species used in the process usually starts at one point near the edge of a cut by tissue factor. This was represented by the point heat source in the model. During plasma treatment, there is an increase in generation of the species that start the biological process of coagulation. The species are created as several points on the wound surface area as opposed to a singular location at the edge of the remaining tissue factor. In order to simulate this, additional point heat sources were added to the model while all other factors from the previous model were controlled and maintained at the same values. The result shown in Fig. 7 was a much more thorough coagulation of the cut domain within the study time range.
It is important to note that at this stage of modeling blood coagulation, focus was put on development of a coagulation mechanism that could possibly simulate the process. As a result, optimization of geometry, flow physics, and boundaries were secondary to the construction of a well-working coagulation model. Ten watts were selected as a working estimation of power for the point heat source. The relationship of temperature to porosity was maintained as a linear function of 1/T. The material chosen for the porous matrix was brick. The Cp was increased to 4000 J/kg•K and the thermal conduc- 
B. Kinetic Coagulation Model
Presented here are illustrative case data resulting from kinetic modeling of plasma influence on concentrations of various blood constituents and key blood coagulation proteins and their complexes, taking place in blood as it coagulates (Figs. 8-37 ).
As can be observed, the tendency is for plasma treatment to increase the concentration of the activated blood coagulation factors (in most cases, large proteins with catalytic activity) and increase the concentration of critical coagulation proteins. In general, from the kinetic modeling we see most of the plasma influence to take place around the 10-s mark, while natural coagulation is activated later. The only conclusion that can be made from this simplified coagulation model thus far is that plasma has some influence on the coagulation cascade and this phenomenon needs to be studied in further detail. In the future we plan to include also the extrinsic pathway, involving platelets.
IV. IN VITRO BLOOD COAGULATION STUDY
A. Calcium Chloride Concentration Experiment
The results from the calcium chloride concentration experiment can be seen in Table 2 . The 7 mM solution coagulated blood more quickly than the 4 mM solution. However, less moisture was left in the 4 mM solution over the same observed time period, evidencing a more complete coagulation reaction. After noting the results and observations of the experiment it was decided that the 4 mM ACN solution was the optimal choice for the following experimentation blood preparation.
B. Measured Viscosity with Plasma Treatment
A graph showing the systolic (high-shear) and diastolic (low-shear) viscosities in millipoise units of each blood sample from the first plasma treatment experiment can be seen in Fig. 38 . Systolic blood viscosity was reported using measurements of blood at a high shear rate of 300 s -1 , and diastolic blood viscosity was measured and reported at a low . As can be seen from Fig. 38 blood viscosity decreased with plasma treatment as evidenced by the drop in diastolic viscosity with increased plasma exposure. This may have been due to the formation of thrombi and heterogeneous regions of hyperviscosity. These thrombi and partially-coagulated portions of blood samples could not be scanned in the capillary viscometer used in this study and therefore had to be separated from the remaining blood, shown in Fig. 39 . This left the remaining less viscous blood to be tested.
Because the coagulated masses and visible thrombi increased with plasma treatment, their physical removal from treated blood samples caused blood viscosity measurements to be lower rather than higher with plasma treatment. This experiment was run a second time. The results are noted in Table 3 .
The trend of decreasing viscosity appeared to continue in this experiment. However, the blood samples for the last two plasma treatments coagulated too quickly for reasonable conclusions to be confirmed. Future studies will employ both capillary viscometers like the Hemathix and rotational viscometers such as the Brookfield to investigate the coagulation effect of plasma on viscosity further.
C. Timed Coagulation with Plasma Treatment
In order to obtain clearer and more consistent results the team altered the procedure as discussed in the Methods and Materials section of this paper. The results are displayed in Table 4 .
It can be seen that plasma exposure does reduce coagulation time. The maximum exposure was limited to 30 s due to material limits of the electrode that was employed to produce the dielectric barrier discharge.
A noteworthy phenomenon that became clear in this experiment was the appearance of structures in the blood samples after plasma treatment, shown in Fig. 38 . While further research towards understanding the consistent appearance of these structures is needed, the origin of the branches may be speculated: they are the coagulated blood surface imprints of the actual plasma discharge streamers when they make contact with (Fig. 40 ). Figure 41 shows the plasma treatment of flowing blood. Due to the complications of 
E. Plasma Treatment with Flowing Blood
VI. CONCLUSIONS
In this article we showed nonequilibrium plasma coagulation of flowing blood. Specif- 
FIG. 41:
The DBD is placed directly on top of the "cut" channel on the bleed plate. A noticeably darker area of blood is visible in the second image (bottom). Due to the large flow rate of the blood coming from the cut, it was difficult to determine what the effect of plasma on active bleeding was. Future tests will be conducted with slower flow rates.
gate the mechanisms of plasma-assisted coagulation of flowing blood.
